All In Biotech

NDA 205598 · Aeterna Zentaris

Macrilen

Macimorelin Acetate · Oral · Growth Hormone Secretagogue Receptor Agonist

NovelOrphanDiscontinued

Last checked: Nov 20, 2026Latest source record: Jul 23, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Dec 20, 2017

Approved uses

2

Original approval plus efficacy supplements

Registered trials

6

3 Phase 3, 0 recruiting

FAERS reports

5

0 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 18, 2026.

MACRILEN is indicated for the diagnosis of adult growth hormone deficiency (AGHD). MACRILEN is a growth hormone (GH) secretagogue receptor agonist indicated for the diagnosis of adult growth hormone deficiency ( 1 ). Limitations of Use : The safety and diagnostic performance has not been established for subjects with BMI > 40kg/m 2 ( 1 ). Limitations of Use The safety and diagnostic performance of MACRILEN have not been established for subjects with a body mass index (BMI) > 40 kg/m 2 .

Mechanism: Macimorelin stimulates GH release by activating growth hormone secretagogue receptors present in the pituitary and hypothalamus.

Therapeutic areas: Endocrinology and women's health

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 23, 2026 Supplement 5 · Efficacy · priority review OrphanLetterLabel
  • Dec 20, 2017 Original approval · Type 1 - New Molecular Entity NovelOrphanLabelLetterReview
1 products under this application
  • MACRILEN · MACIMORELIN ACETATE EQ 60MG BASE/POUCH · FOR SOLUTION, ORAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Macimorelin" as an intervention, any sponsor and status, largest first.

All 6 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • bradycardia1
  • dizziness1
  • dysgeusia1
  • fatigue1
  • feeling hot1
  • fluid retention1
  • flushing1
  • nausea1
  • off label use1
  • product communication issue1
  • therapeutic product effect variable1
  • wrong technique in product usage process1

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20192
20203

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 4 on PubMed

Sponsor: Aeterna Zentaris

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.